DDInter1826 DDInter636
A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for clinical use given its lack of specificity and significant gastrointestinal side effects. Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. The development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014. As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold). Empagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart failure regardless of ejection fraction.[L40783,L13916]
Tolazamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Tolazamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Empagliflozin
Tolazamide {u} (Compound) resembles {v} (Compound) Sulfacetamide
Sulfacetamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Tolazamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Timolol
Timolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Tolazamide {u} (Compound) resembles {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Tolazamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Vilanterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Tolazamide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Glimepiride
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Tolazamide {u} (Compound) binds {v} (Gene) KCNJ1
KCNJ1 {u} (Gene) is bound by {v} (Compound) Minoxidil
Minoxidil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Tolazamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may lead to a major life threatening interaction when taken with {v} Gemifloxacin
Gemifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Tolazamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methyldopa
Methyldopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Tolazamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Tolazamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Empagliflozin
Tolazamide (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Tolazamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Tolazamide (Compound) resembles Gliclazide (Compound) and Gliclazide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Tolazamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Tolazamide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Tolazamide (Compound) binds KCNJ1 (Gene) and KCNJ1 (Gene) is bound by Minoxidil (Compound) and Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Tolazamide (Compound) resembles Glipizide (Compound) and Glipizide may lead to a major life threatening interaction when taken with Gemifloxacin and Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Tolazamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a minor interaction that can limit clinical effects when taken with Methyldopa and Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin